07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

VeraCode Genotyping Test for Factor V regulatory update

FDA granted 510(k) clearance for Illumina's VeraCode Genotyping Test for Factor II (Prothrombin) and Factor V (Leiden), genetic markers associated with thrombosis. The test, which combines Illumina's VeraCode digital microbead technology and assay chemistry, runs...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

BeadXpress regulatory update

FDA granted 510(k) clearance for the Illumina's BeadXpress system as an in vitro diagnostic device intended for the simultaneous detection of multiple analytes in a DNA sample utilizing VeraCode holographic microbead technology. The system was...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

Affymetrix, Illumina microarrays news

Illumina agreed to pay Affymetrix $90 million to resolve the companies' patent litigation relating to methods and apparatuses for analyzing unknown polymer sequences using microarrays of known polymer sequences. Illumina will make the one-time payment...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Illumina sales and marketing update

LIMN launched its BeadXpress multiplex assay system to perform DNA, RNA and protein-based assays. BeadXpress is based on ILMN's VeraCode digital microbead technology. Illumina Inc. (ILMN), San Diego, Calif.   Business: Diagnostic   ...
07:00 , Mar 19, 2007 |  BioCentury  |  Strategy

Illumina's line in the sand

Illumina Inc. said a jury's decision that the company infringes five patents held by fellow microarray competitor Affymetrix Inc. is a mere bump in the road, as the disputed products in the suit are based...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

Illumina, Children's Hospital of Eastern Ontario deal

The parties will jointly develop molecular diagnostics to screen newborns for spinal muscular atrophy (SMA) and hemoglobinopathies. The diagnostics will use ILMN's VeraCode digital microbead technology, which detects SNPs, mRNA and proteins, and will run...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

Illumina, ReaMetrix Inc. deal

ReaMetrix will develop and validate molecular diagnostic panels for use on ILMN's BeadXpress technology. ILMN will supply its VeraCode digital microbead technology and other reagents for the tests. ReaMetrix will have nonexclusive marketing rights...
07:00 , May 22, 2006 |  BC Week In Review  |  Company News

deCode, Illumina deal

DCGN and ILMN partnered to develop and commercialize diagnostic tests for gene variants discovered by DCGN using ILMN's high-multiplex SNP genotyping platform. The partners will jointly validate biomarkers, and ILMN will sell resulting diagnostic panels...
01:20 , May 16, 2006 |  BC Extra  |  Company News

deCode, Illumina in diagnostic deal

DCGN and ILMN partnered to develop and commercialize diagnostic tests for gene variants discovered by DCGN using ILMN's high-multiplex SNP genotyping platform. The partners will jointly validate biomarkers, and ILMN will sell resulting diagnostic panels...